Drug Profile
BCT 200
Alternative Names: BCT-200Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Bio-Cancer Treatment International
- Class Polyethylene glycols; Ureohydrolases
- Mechanism of Action Arginase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Graft-versus-host disease; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Graft-versus-host-disease in Hong Kong (IV, Infusion)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in Hong Kong (IV, Infusion)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Hong Kong (IV, Infusion)